NCT05828004Completed
The SHINE-MDT Randomized Controlled Trial
Effect of Multidisciplinary Team Support on Head and Neck Cancer Patients Receiving Radiotherapy: The SHINE-MDT Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 28 Aug 2025
Brief summary (registry, in English)
Radiotherapy is one of the main treatments for head and neck Carcinoma. The incidence of radiotherapy-related adverse events is greater than 90%, and severe adverse events may lead to the interruption of radiotherapy. The management of nutritional, psychological, and rehabilitative issues in patients undergoing radiotherapy for head and neck cancer presents unique clinical challenges. We aimed to evaluate the efficacy of the SHINE-MDT (Supportive Holistic Interventions by Nurses and Experts via Multidisciplinary Team) in reducing radiotherapy interruptions and improving patients' quality of life (QoL) compared with usual care.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 233 (actual)
- First submitted
- 2 Feb 2023
- Start date
- 27 Apr 2023
- Primary completion date
- 1 Dec 2023
- Lead sponsor
- West China Hospital
- Diseases
- Head and neck cancer
- NCT number
- NCT05828004
What you commit to
- Study type: Interventional
- Participants enrolled: 233
- From 27 Apr 2023 to the primary completion date, 1 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A history of prior head and neck radiotherapy;
Other illness
- Presence of other malignant tumors aside from head and neck malignancies;
- Mental illness or cognitive impairments;
- Uncontrolled systemic diseases that could significantly affect their QoL
Who the study is looking for
- Patients had pathologically confirmed malignant head and neck tumors without distant metastasis.
- Patient age ≥18 years;
- Patients were scheduled to undergo either postoperative adjuvant radiotherapy or radical radiotherapy, with or without concurrent chemotherapy.
- Baseline ECOG (Eastern Cooperative Oncology Group) score 0-2;
- Good cognitive and reading skills, able to complete the questionnaire survey.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| West China Hospital，Sichuan University Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
Related publications
- Multidisciplinary Team Support for Patients With Head and Neck Cancer Receiving Radiotherapy: A Randomized Clinical Trial.JAMA Netw Open · 2025 · PMID 41396606
This page is information, not medical advice. Discuss any trial with your doctor.